Joseph Anthony Mara Jr Sells 5,000 Shares of Vericel (NASDAQ:VCEL) Stock

Vericel Corporation (NASDAQ:VCEL – Get Free Report) CFO Joseph Anthony Mara, Jr. sold 5,000 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $44.75, for a total transaction of $223,750.00. Following the completion of the transaction, the chief financial officer directly owned 16,009 shares of the company’s stock, valued at $716,402.75. This trade represents a 23.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Vericel Stock Down 1.3%

VCEL traded down $0.58 during midday trading on Tuesday, reaching $44.49. 743,265 shares of the company’s stock were exchanged, compared to its average volume of 621,141. The business has a 50-day simple moving average of $36.33 and a two-hundred day simple moving average of $35.85. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of 105.93 and a beta of 1.12. Vericel Corporation has a one year low of $28.95 and a one year high of $46.62.

Get Vericel alerts:

Vericel (NASDAQ:VCEL – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03. Vericel had a return on equity of 6.41% and a net margin of 7.35%.The company had revenue of $68.43 million for the quarter, compared to analyst estimates of $63.68 million. During the same period in the prior year, the company posted ($0.23) EPS. The company’s revenue was up 30.1% compared to the same quarter last year. As a group, research analysts anticipate that Vericel Corporation will post 0.49 EPS for the current fiscal year.

Analysts Set New Price Targets

VCEL has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $64.00 price objective on shares of Vericel in a report on Friday, May 8th. Weiss Ratings raised Vericel from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 16th. Leerink Partners restated an “outperform” rating and set a $46.00 price target on shares of Vericel in a research report on Tuesday, March 10th. Truist Financial dropped their price target on Vericel from $48.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. Finally, Wall Street Zen downgraded Vericel from a “buy” rating to a “hold” rating in a research report on Sunday, June 14th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vericel currently has a consensus rating of “Hold” and a consensus price target of $52.50.

Check Out Our Latest Analysis on VCEL

Hedge Funds Weigh In On Vericel

A number of large investors have recently modified their holdings of the stock. Huntington National Bank grew its stake in shares of Vericel by 51.3% during the third quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 273 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Vericel in the 4th quarter worth approximately $27,000. Quarry LP acquired a new position in Vericel during the 4th quarter worth $31,000. Farther Finance Advisors LLC lifted its holdings in Vericel by 116.5% during the 4th quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock worth $35,000 after buying an additional 522 shares in the last quarter. Finally, Truvestments Capital LLC lifted its holdings in Vericel by 175.4% during the 4th quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock worth $55,000 after buying an additional 977 shares in the last quarter.

About Vericel

(Get Free Report)

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.

Featured Articles

• Five stocks we like better than Vericel
• NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
• Amazon Could Be About to Reap the Rewards of a Software Spending Boom
• Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
• AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.